PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
05-Mar-2024 NovAliX and Max Planck join forces to advance Cryo-EM driven drug discovery  Andrew Lloyd Associates
04-Mar-2024 CSL Behring Signs First Commercial Agreement in Austria to Fund Haemophilia B Gene Therapy HEMGENIX® CSL Behring
04-Mar-2024 Carthera: positive results from phase I/II clinical trial of SonoCloud-9 in treatment of glioblastoma published in Nature Communications Andrew Lloyd Associates
04-Mar-2024 Q&M Dental Group recorded growth in both Revenue and Net Profit after tax attributable to parent of S$182.7 million and S$11.5 million respectively for FY2023 Q&M Dental Group Singapore Ltd
04-Mar-2024 Alfa Chemistry Diversifies Supply of Active Pharmaceutical Ingredients for Pharmaceutical Preparation Alfa Chemistry
04-Mar-2024 Alfa Chemistry Expands Selection of Click Chemistry Reagents: DBCO, BCN, and Tetrazines Included Alfa Chemistry
01-Mar-2024 4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby) 4SC
01-Mar-2024 Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations Evaxion
01-Mar-2024 CryoCloud secures a €500k pre-seed investment to accelerate structure-based drug design with their cloud-native cryo-EM data analysis platform CryoCloud
01-Mar-2024 AsiaMedic achieves record revenue of S$23.5 million for FY2023 amid expansion of its medical imaging and aesthetics businesses AsiaMedic Limited
01-Mar-2024 Q&M Dental Group recorded growth in both Revenue and Net Profit after tax attributable to parent of S$182.7 million and S$11.5 million respectively for FY2023 Q&M Dental Group Singapore Ltd
29-Feb-2024 Leading biotech awarded second FDA Orphan Drug Designation to boost search for rare disease therapies SynaptixBio
29-Feb-2024 Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma Ariceum Therapeutics
29-Feb-2024 Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling Neobe Therapeutics
29-Feb-2024 Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma Ariceum Therapeutics
29-Feb-2024 Global biotechnology leader, Lifebit, achieves a groundbreaking milestone, unlocking the potential of diverse data to accelerate pharmaceutical research and development. Lifebit
29-Feb-2024 Capricorn Scientific and ExcellGene Form Strategic Partnership to Support Biotech Industries Capricorn Scientific and ExcellGene
29-Feb-2024 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases PulseSight Therapeutics
28-Feb-2024 Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report Avance Clinical
28-Feb-2024 Driving Genomic Research Forward with Advanced CRISPR Sequencing by CD Genomics CD Genomics